AbbVie Inc (ABBV)
Receivables turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Revenue | US$ in thousands | 56,334,000 | 54,318,000 | 58,054,000 | 56,197,000 | 45,804,000 |
Receivables | US$ in thousands | — | — | — | — | — |
Receivables turnover | — | — | — | — | — |
December 31, 2024 calculation
Receivables turnover = Revenue ÷ Receivables
= $56,334,000K ÷ $—K
= —
The data provided indicates that the receivables turnover for AbbVie Inc is not available for the years December 31, 2020 to December 31, 2024. As receivables turnover is a crucial ratio that measures how efficiently a company is able to collect outstanding receivables from its customers, the absence of this information hinders a comprehensive analysis of AbbVie Inc's ability to manage its accounts receivable effectively over the specified period. It is important for investors and stakeholders to closely monitor this ratio to assess the company's liquidity and operational efficiency.
Peer comparison
Dec 31, 2024
Company name
Symbol
Receivables turnover
AbbVie Inc
ABBV
—
Abbott Laboratories
ABT
—
ACADIA Pharmaceuticals Inc
ACAD
—
Alkermes Plc
ALKS
4.05
Amphastar P
AMPH
5.37
ANI Pharmaceuticals Inc
ANIP
—
Arcus Biosciences Inc
RCUS
51.60
Biomarin Pharmaceutical Inc
BMRN
4.31
Bristol-Myers Squibb Company
BMY
4.49
Catalyst Pharmaceuticals Inc
CPRX
—
Collegium Pharmaceutical Inc
COLL
—